p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
| Autor: | Evguenia M. Alexandrova, S Xu, Ramona Schulz-Heddergott, Ute M. Moll, Safia A Mirza, Natalia D. Marchenko |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Cancer Research Immunology Mutant Mutation Missense Loss of Heterozygosity Breast Neoplasms Biology Metastasis Loss of heterozygosity 03 medical and health sciences Cellular and Molecular Neuroscience Mice In vivo Cell Line Tumor medicine Missense mutation Animals Humans Allele Alleles Cell Biology medicine.disease Molecular biology 3. Good health 030104 developmental biology Gain of function Cell culture Cancer research Female Original Article Tumor Suppressor Protein p53 |
| Zdroj: | Cell Death & Disease |
| ISSN: | 2041-4889 |
| Popis: | Missense mutations in TP53 comprise >75% of all p53 alterations in cancer, resulting in highly stabilized mutant p53 proteins that not only lose their tumor-suppressor activity, but often acquire oncogenic gain-of-functions (GOFs). GOF manifests itself in accelerated tumor onset, increased metastasis, increased drug resistance and shortened survival in patients and mice. A known prerequisite for GOF is mutant p53 protein stabilization, which itself is linked to aberrant protein conformation. However, additional determinants for mutant p53 stabilization likely exist. Here we show that in initially heterozygous mouse tumors carrying the hotspot GOF allele R248Q (p53Q/+), another necessary prerequisite for mutant p53 stabilization and GOF in vivo is loss of the remaining wild-type p53 allele, termed loss-of-heterozygosity (LOH). Thus, in mouse tumors with high frequency of p53 LOH (osteosarcomas and fibrosarcomas), we find that mutant p53 protein is stabilized (16/17 cases, 94%) and tumor onset is significantly accelerated compared with p53+/− tumors (GOF). In contrast, in mouse tumors with low frequency of p53 LOH (MMTV-Neu breast carcinomas), mutant p53 protein is not stabilized (16/20 cases, 80%) and GOF is not observed. Of note, human genomic databases (TCGA, METABRIC etc.) show a high degree of p53 LOH in all examined tumor types that carry missense p53 mutations, including sarcomas and breast carcinomas (with and without HER2 amplification). These data – while cautioning that not all genetic mouse models faithfully represent the human situation – demonstrate for the first time that p53 LOH is a critical prerequisite for missense mutant p53 stabilization and GOF in vivo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|